The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice
Open accessAbstract
An orally bioavailable and blood–brain barrier penetrating analog of the kinase inhibitor K252a was able to prevent the typical motor deficits in the tau (P301L) transgenic mouse model (JNPL3) and markedly reduce soluble aggregated hyperphosphorylated tau. However, neurofibrillary tangle counts were not reduced in the successfully treated cohort, suggesting that the main cytotoxic effects of tau are not exerted by neurofibrillary tangles but by lower molecular mass aggregates of tau. Our findings strongly suggest that abnormal tau hyperphosphorylation plays a critical role in the development of tauopathy and suggest a previously undescribed treatment strategy for neurodegenerative diseases involving tau pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., Pickering-Brown, S., Chakraverty, S., Isaacs, A., Grover, A., et al. (1998) · Nature · doi:10.1038/31508 · Cited by 3,498
Self-citationInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia
Spillantini, M. G., Murrell, J. R., Goedert, M., Farlow, M. R., Klug, A., & Ghetti, B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7737 · Cited by 1,474
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Self-citationCell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases
Selkoe, D. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1104-1054 · Cited by 863
Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer disease.
Alonso, A. C., Zaidi, T., Grundke-Iqbal, I., & Iqbal, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5562 · Cited by 738
Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer‐like state.
Drewes, G., Lichtenberg‐Kraag, B., Döring, F., Mandelkow, E. M., Biernat, J., Goris, J., Dorée, M., & Mandelkow, E. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05272.x · Cited by 565
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms
Andorfer, C., Acker, C. M., Kress, Y., Hof, P. R., Duff, K., & Davies, P. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4637-04.2005 · Cited by 511
Pei, J.-J., Braak, H., An, W.-L., Winblad, B., Cowburn, R. F., Iqbal, K., & Grundke-Iqbal, I. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00488-6 · Cited by 247
Cited by
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717
“Attenuation of tau phosphorylation levels is indeed considered to offer a route to slowing or even halting disease progression in people suffering from AD, and accordingly intense efforts are currently focused on developing kinase inhibitors for therapeutic benefi”
BackgroundŠimić, G., Babić Leko, M., Wray, S., Harrington, C., Delalle, I., Jovanov-Milošević, N., Bažadona, D., Buée, L., De Silva, R., Di Giovanni, G., et al. (2016) · Biomolecules · doi:10.3390/biom6010006 · Cited by 703
Gong, C.-X., & Iqbal, K. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708785909111 · Cited by 644
Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611
Wang, J.-Z., Xia, Y.-Y., Grundke-Iqbal, I., & Iqbal, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129031 · Cited by 532
Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy
Berger, Z., Roder, H., Hanna, A., Carlson, A., Rangachari, V., Yue, M., Wszolek, Z., Ashe, K., Knight, J., Dickson, D., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0587-07.2007 · Cited by 485
Self-citationThe role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
The importance of tau phosphorylation for neurodegenerative diseases
Noble, W., Hanger, D. P., Miller, C. C. J., & Lovestone, S. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00083 · Cited by 475
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
“This raises the possibility that PHF-tau, and perhaps other soluble lower-mass hyperphosphorylated tau aggregates, might induce neurodegeneration owing to loss of the normal function of these tau forms rather than accumulation of toxic NFT”
BackgroundAdvances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2959 · Cited by 440
The Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J.-Z., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 398
Therapeutic approaches to Alzheimer's disease
Klafki, H.-W., Staufenbiel, M., Kornhuber, J., & Wiltfang, J. (2006) · Brain · doi:10.1093/brain/awl280 · Cited by 362
Self-citationPassive Immunization with Anti-Tau Antibodies in Two Transgenic Models
Chai, X., Wu, S., Murray, T. K., Kinley, R., Cella, C. V., Sims, H., Buckner, N., Hanmer, J., Davies, P., O'Neill, M. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.229633 · Cited by 351
Self-citationThe Revitalized Tau Hypothesis on Alzheimer's Disease
Maccioni, R. B., Farías, G., Morales, I., & Navarrete, L. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.03.007 · Cited by 312
Congdon, E. E., Wu, J. W., Myeku, N., Figueroa, Y. H., Herman, M., Marinec, P. S., Gestwicki, J. E., Dickey, C. A., Yu, W. H., & Duff, K. E. (2012) · Autophagy · doi:10.4161/auto.19048 · Cited by 297
Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud, S., Jones, D. R., Moussaud-Lamodière, E. L., Delenclos, M., Ross, O. A., & McLean, P. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-43 · Cited by 287
van Eersel, J., Ke, Y. D., Liu, X., Delerue, F., Kril, J. J., Götz, J., & Ittner, L. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009038107 · Cited by 284
Tau-based therapies in neurodegeneration: opportunities and challenges
Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272
The Emerging Link between O-GlcNAc and Alzheimer Disease
Zhu, Y., Shan, X., Yuzwa, S. A., & Vocadlo, D. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.601351 · Cited by 267
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
Kitazawa, M., Medeiros, R., & M. LaFerla, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799315786 · Cited by 178
“Recent evidence suggests that soluble intermediates or oligomeric tau species, not aggregated tau or NFTs, are responsible in triggering neuronal death [14, 15].”
BackgroundmiR‐132 loss de‐represses ITPKB and aggravates amyloid and TAU pathology in Alzheimer's brain
Salta, E., Sierksma, A., Vanden Eynden, E., & De Strooper, B. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606520 · Cited by 169
Cavallini, A., Brewerton, S., Bell, A., Sargent, S., Glover, S., Hardy, C., Moore, R., Calley, J., Ramachandran, D., Poidinger, M., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.463984 · Cited by 133
“(40) used an analog of K252a (SRN-003-556), amolecule that inhibits GSK3, Erk2, CDK1, PKA, and protein kinase C with equal efficacies, on JNPL3 tau transgenic mice and showed decreased hyperphosphorylated tau and improved motor impairments.”
MethodSelf-citationDeveloping therapeutic approaches to tau, selected kinases, and related neuronal protein targets
Lee, V. M.-Y., Brunden, K. R., Hutton, M., & Trojanowski, J. Q. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006437 · Cited by 122
Self-citationThe Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology
Cárdenas-Aguayo, M. D. C., Gómez-Virgilio, L., DeRosa, S., & Meraz-Ríos, M. A. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500148z · Cited by 120
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
S/P and T/P phosphorylation is critical for tau neurotoxicity in Drosophila
Steinhilb, M. L., Dias‐Santagata, D., Mulkearns, E. E., Shulman, J. M., Biernat, J., Mandelkow, E., & Feany, M. B. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21232 · Cited by 107
Mediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98
Rational therapeutic approaches to progressive supranuclear palsy
Stamelou, M., de Silva, R., Arias-Carrion, O., Boura, E., Hollerhage, M., Oertel, W. H., Muller, U., & Hoglinger, G. U. (2010) · Brain · doi:10.1093/brain/awq115 · Cited by 91
The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics
Pritchard, S. M., Dolan, P. J., Vitkus, A., & Johnson, G. V. W. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01273.x · Cited by 89
“Furthermore, inhibition of tau hyperphosphorylation in the JNPL3 mouse model which expresses tau with an FTDP-17 mutation attenuated the severe motor deficits and reduced the amount of soluble tau aggregates without affecting NFT counts [74].”
BackgroundTargeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
Self-citationStygelbout, V., Leroy, K., Pouillon, V., Ando, K., D’Amico, E., Jia, Y., Luo, H. R., Duyckaerts, C., Erneux, C., Schurmans, S., et al. (2014) · Brain · doi:10.1093/brain/awt344 · Cited by 85
Kinase activities increase during the development of tauopathy in htau mice
Kelleher, I., Garwood, C., Hanger, D. P., Anderton, B. H., & Noble, W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04930.x · Cited by 78
Tau Aggregation in Alzheimer's Disease: What Role for Phosphorylation?
Lippens, G., Sillen, A., Landrieu, I., Amniai, L., Sibille, N., Barbier, P., Leroy, A., Hanoulle, X., & Wieruszeski, J.-M. (2007) · Prion · doi:10.4161/pri.1.1.4055 · Cited by 68
Perea, J. R., Ávila, J., & Bolós, M. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.08.007 · Cited by 54
Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer’s Disease
Kang, Y. J., Diep, Y. N., Tran, M., & Cho, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249591 · Cited by 36
“5 [34] Lithium GSK3-β inhibitor Phase II 71/NA/NA [35] Amino-thiazole GSK3-β inhibitor In vitro Sf21 cells [36] Thiadiazolidinone GSK3-β inhibitor In vitro Kinase assay [37] Sirenade GSK3-β inhibitor In vivo Wistar rats/Male [38] R-roscovitine CDK inhibitor In vivo Wistar rats/Both [39] Aloisine CDK inhibitor In vitro…”
Method
Metadata
- Authors
- Le Corre, S., Klafki, H. W., Plesnila, N., Hübinger, G., Obermeier, A., Sahagún, H., Monse, B., Seneci, P., Lewis, J., Eriksen, J., Zehr, C., Yue, M., McGowan, E., Dickson, D. W., Hutton, M., & Roder, H. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2006-06-20
- Volume
- 103
- Issue
- 25
- Pages
- 9673-9678
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2128121742
- Cited by
- 221
- References
- 9
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.